GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs

Annals of Pharmacotherapy

Volumn 40, Issue 11, 2006, Pages 1924-1931

  Harris, Crystal L ^a,f   Raisch, Dennis W ^b   Abhyankar, Upendra ^c   Marfatia, Shalaka ^d   Campbell, Heather M ^e   Sather, Mike R ^e  

^a VA Medical Center   (United States)

^b Scientific Affairs   (United States)

^c Life Sciences Digital Business Operations   (India)

^d UNITED BIOSOURCE CORPORATION   (United States)

^e VA Cooperative Studies Program Clinical Research Pharmacy   (United States)

^f University of New Mexico   (United States)

Author keywords

Gastrointestinal bleeding; Nonsteroidal antiinflammatory agents

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETODOLAC; FAMOTIDINE; FLURBIPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; LANSOPRAZOLE; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXAPROZIN; PANTOPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; RABEPRAZOLE; ROFECOXIB; SALSALATE; SULINDAC; TOLMETIN;

ADOLESCENT; ADULT; AGED; ARTICLE; COMORBIDITY; CORTICOSTEROID THERAPY; COST OF ILLNESS; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; VETERAN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DATABASES, FACTUAL; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GUIDELINES; HUMANS; MALE; MIDDLE AGED; PROTECTIVE AGENTS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 33750994079     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H183     Document Type: Article

References (46)

1. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995;155:1949-56.
2. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001;41:192-9.
3. Woodwell D, Cherry D. National Ambulatory Medical Care Survey: 2002 summary. Adv Data 2004:1-44.
4. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-9.
5. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998;51:8-16.
6. Johnson RE, Hornbrook MC, Hooker RS, Woodson GT, Shneidman R. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation. Pharmacoeconomics 1997;12:76-88.
7. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213-22.
8. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82.
9. White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics 1999;15:445-58.
10. Wilcox CM, Alexander LN, Cotsonis GA, Clark WS. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997;42:990-7.
11. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
12. James MW, Hawkey CJ. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. Br J Clin Pharmacol 2003;56:146-55.
13. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
14. Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 2002;69(suppl 1):SI40-6.
15. Scheiman JM. Gastrointestinal outcomes: evidence for risk reduction in patients using coxibs. Am J Manag Care 2002;8:S518-28.
16. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005;165:171-7.
17. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
18. Psaty BM, Furberg CD. COX-2 inhibitors-lessons in drug safety. N Engl J Med 2005;352:1133-5.
19. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
20. Department of Veterans Affairs Medical Advisory Panel and Pharmacy Benefits Management Strategic Healthcare Group. Criteria for use of COX-II inhibitors in veteran patients. Washington, DC: Department of Veterans Affairs, 2000.
21. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105(suppl):31S-8S.
22. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26(suppl 56):18-24.
23. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004;50:2433-40.
24. Sweet BV, Townsend KA, Tsai CY. Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients. Am J Health Syst Pharm 2004;61:1917-21.
25. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2 p following 1528.
26. Jacobsen RB, Phillips BB. Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs. Ann Pharmacother 2004;38:1469-81. Epub 22 Jun 2004. DOI 10.1345/aph.1D621
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
28. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.
29. Selim AJ, Fincke G, Ren XS, et al. Comorbidity assessments based on patient report: results from the Veterans Health Study. J Ambul Care Manage 2004;27:281-95.
30. Manns B, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol 2003;60:341-51.
31. Survey of Healthcare Experiences of Inpatient Care (SHEP). Vol. 2005: The NRC Picker Group. eReports 2004. http://thenrcpickergroup.com (accessed 2005 Apr 14).
32. Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005;129:1171-8.
33. Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M. Underutilization of gastroprotective measures in patients receiving non-steroidal antiinflammatory drugs. Arthritis Rheum 2002;46:2195-200.
34. Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford, England) 2003;42(suppl 3):iii23-31.
35. Fick DM, Maclean JR, Rodriguez NA, et al. A randomized study to decrease the use of potentially inappropriate medications among community-dwelling older adults in a southeastern managed care organization. Am J Manag Care 2004;10:761-8.
36. Raisch DW, Sleath BL. Using feedback letters to influence the use of antiulcer agents in a Medicaid program. J Gen Intern Med 1999;14:145-50.
37. Raisch DW, Bootman JL, Larson LN, McGhan WF. Improving antiulcer agent prescribing in a health maintenance organization. Am J Hosp Pharm 1990;47:1766-73.
38. Raisch DW. A model of methods for influencing prescribing: part II. A review of educational methods, theories of human inference, and delineation of the model. DICP 1990;24:537-42.
39. Scheiman JM. Nonsteroidal anti-inflammatory drugs, aspirin, and gastrointestinal prophylaxis: an ounce of prevention. Rev Gastroenterol Disord 2005;5(suppl2):39-49.
40. Weideman RA, Kelly KC, Kazi S, et al. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. Gastroenterology 2004;127:1322-8.
41. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 2004;291:1850-6.
42. Bernal-Delgado E, Galeote-Mayor M, Pradas-Arnal F, Peiro-Moreno S. Evidence based educational outreach visits: effects on prescriptions of non-steroidal anti-inflammatory drugs. J Epidemiol Community Health 2002;56:653-8.
43. Dranitsaris G, Leung P, Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 2001;9:611-8.
44. McMullin ST, Lonergan TP, Rynearson CS, Doerr TD, Veregge PA, Scanlan ES. Impact of an evidence-based computerized decision support system on primary care prescription costs. Ann Fam Med 2004;2:494-8.
45. Ofman JJ, Badamgarav E, Henning JM, Knight K, Laine L. Utilization of nonsteroidal anti-inflammatory drags and antisecretory agents: a managed care claims analysis. Am J Med 2004;116:835-42.
46. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004;351:2187-94.